Research design and patient population
death, primary breast cancer, Cancer
BRAIN METASTASIS, PRIMARY TUMORS, LUNG METASTASIS, BLOOD, BONE METASTASIS, PRIMARY TUMOR, LIVER METASTASIS, CANCER
This was a retrospective study based on patients’ records. From 2010 to 2022, 679 BC patients with bone metastasis were treated in the Cancer Hospital of Shantou University Medical College. We applied strict inclusion and exclusion criteria during the enrollment process. Patients met the following inclusion criteria: (1) were diagnosed as primary breast cancer with histopathological analysis; (2) had no other primary tumors; (3) were confirmed with bone metastasis by bone scan and/or CT [Flow chart of the study.In the enrolled patients, comprehensive datasets for the relevant parameters (including clinical factors, results of laboratory examination before treatment of bone metastasis, and survival information) were provided. The clinical factors that may be relevant to prognosis were collected, including age, treatment of primary tumor, estrogen receptor (ER) status, progesterone receptor (PR) status, human epidermal growth factor receptor 2 (Her2) status, histological type, T stage, lymph node metastasis, liver metastasis, brain metastasis and lung metastasis. The laboratory examination indicators contained blood routine and biochemical examination. Blood routine included white blood cell count (WBC), red blood cell count (RBC), hemoglobin (HGB), red blood cell specific volume (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), platelet count (PLT), lymphocyte ratio (LY%), monocyte ratio (MO%), and neutrophil ratio (NE%). Biochemical examination enrolled lactate dehydrogenase (LDH), alkaline phosphatase (ALP), γ-glutamyl transpeptidase (GGT), total protein (TP), albumin (ALB), globulin (GLB), glucose (GLU), blood urea nitrogen (BUN), creatinine (CREAT), uric acid (UA), calcium (Ca), and serum phosphonium (Pi). In this study, the primary endpoint was overall survival (OS), calculated from the date of BC bone metastasis diagnosis to death or last follow-up time.